BioAdvance
-
Radnor Startup Develops Therapies for Rare Conditions with No Current Treatment
Radnor startup Palvella Therapeutics is tackling rare conditions that currently have no approved treatment, writes John George for the Philadelphia Business Journal. The company was…
-
Radnor-Based Biotech Company Raises $800,000 in Funding
Radnor’s Opsidio, which is working on developing monoclonal antibodies for treatment of fibrotic diseases, has raised $800,000 through a debt financing deal, writes John George…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
